Article Detail - JF Part A
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R7 - Effective July 11, 2024
Date Posted: July 11, 2024
This Local Coverage Article (LCA) has been revised under contractor numbers: 02101 (AK), 02201 (ID), 02301 (OR), 02401 (WA), 03101 (AZ), 03201 (MT), 03301 (ND), 03401 (SD), 03501 (UT), and 03601 (WY).
Effective Date: July 11, 2024
Summary of Changes:
Under Article Text revised Table 1 row 3 to add "RaDaR Whole Exome + Plasma Series Bundle for Molecular Residual Disease (NeoGenomics Laboratories, Inc)". Under subheading Additional Test-specific Indications, Limitations and Instructions revised first sentence to add "HPV-negative head and neck squamous cell carcinoma (RaDaR)". Formatting was corrected throughout the article. This revision is due to new covered test that has successfully completed a TA and is effective for 3/20/2024.
Under CPT/HCPCS Codes Group 3: Codes added 81479. This is effective 7/11/2024.
Visit the Noridian Active LCDs webpage to view the document or access it via the CMS MCD.